From: Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis
Study (Ref) | Random Sequence Generation | Allocation Concealment | Selective Reporting | Other Bias | Blinding | Incomplete outcome data | BIAS judgement |
---|---|---|---|---|---|---|---|
Flood-Page et al. 2007 [50] | Unclear | Unclear | Low | High | Unclear | Low | High Risk |
Busse et al. 2008 [68] | Unclear | Unclear | Low | Unclear | Low | Low | High Risk |
Haldar et al. 2009 [49] | Low | Unclear | Low | Unclear | Unclear | Low | Intermediate Risk |
Corren et al. 2011 [18] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Castro et al. 2011 [54] | Unclear | Unclear | Low | Unclear | Low | Low | Intermediate Risk |
Pavord et al. 2012 [15] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Noonan et al. 2013 [57] | Unclear | Unclear | Low | Unclear | Unclear | Low | High Risk |
Wenzel et al. 2013 [65] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Oh et al. 2013 [20] | Low | Low | Unclear | Unclear | Low | Unclear | Low Risk |
Piper et al. 2013 [59] | Low | Unclear | Low | Unclear | Unclear | Low | Intermediate Risk |
De Boever et al. 2014 [62] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Ortega et al. 2014 [36] | Low | Unclear | Low | Unclear | Low | Unclear | Intermediate Risk |
Castro et al. 2014 [42] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Hanania et al. 2015 [33] | Low | Low | Unclear | Unclear | Low | Low | Intermediate Risk |
Brightling et al. 2015 [61] | Low | Low | Low | Unclear | Unclear | Low | Intermediate Risk |
Castro et al. 2015 [37] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Hanania et al. 2016 [34] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Bjermer et al. 2016 [53] | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | High Risk |
Corren et al. 2016 [52] | Unclear | Unclear | Low | Unclear | Unclear | Low | High Risk |
Bleecker et al. 2016 [38] | Low | Unclear | Low | Unclear | Low | Low | Intermediate Risk |
FitzGerald et al. 2016 [39] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Park et al. 2016 [40] | Low | Unclear | Low | Low | Low | Low | Low Risk |
Nowak et al. 2016 [41] | Low | Unclear | Low | Unclear | Low | Low | Intermediate Risk |
Wenzel et al. 2016 [64] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Corren et al. 2017 [13] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Chupp et al. 2017 [48] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Ferguson et al. 2017 [46] | Low | Low | Low | Unclear | Low | High | Intermediate Risk |
Panettieri et al. 2018 [35] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Russel et al. 2018 [60] | Low | Low | Low | Unclear | Low | Low | Low Risk |
Castro et al. 2018 [19] | Low | Unclear | Low | High | Low | Low | High Risk |